


China's Innovative Drugs: Market Growth Backed by Research Strength

Xin Wu, CIO | June 12, 2025

The Hang Seng Stock Connect Hong Kong Innovative Drug Index surged 61.91% year-to-date through June 9th, becoming a benchmark for global innovative drug investment. After years of refinement, China's Innovative Drug sector has sprouted globally competitive enterprises.

The latest IQVIA report, Global Oncology Trends 2025, reveals that in 2024, oncology clinical trials initiated by Chinese companies accounted for 39% of the global total, surpassing the United States (32%) and Europe (20%) to rank first worldwide. This proportion marks a dramatic leap from a mere 2% in 2009, reflecting a profound transformation in China's pharmaceutical innovation ecosystem over 15 years of rapid growth.

Exhibit 3: Number and share of oncology trial starts by company headquarters location, 2009–2024



Source: Cyteline Trialtrave, Jan 2025; IQVIA Institute, Apr 2025.

This rapid industry growth has been shaped by a multitude of forces. A continuously optimized regulatory environment—including policies such as accelerated approval by the National Medical Products Administration (NMPA) and dynamic adjustments to the national reimbursement drug list (NRDL)—has significantly reduced the time-to-market for innovative domestic drugs. Over the past five years, the number of novel oncology agents (NAS) approved in China surged to 84, nearly matching the US (85), with 45 being China-exclusive innovations—including 10 PD-1/PD-L1 inhibitors and 4 CAR-T therapies. This signals China's shift from a "follower" to an "originator," building a distinctive R&D model with local characteristics.

Overall, China is making significant progress in the field of innovative drug development, supported by key strengths such as robust government backing for biotech research, efficient clinical trial recruitment processes, and well-integrated biotech clusters comprising skilled professionals, emerging enterprises, and contract research organizations.

Disclosures

This document has been provided to you solely for information purposes and does not constitute an offer or solicitation of an offer or any advice or recommendation to purchase any securities or other financial instruments and may not be construed as such. The factual information set forth herein has been obtained or derived from sources believed by the author and Banyan Partners to be reliable but it is not necessarily all-inclusive and is not guaranteed as to its accuracy and is not to be regarded as a representation or warranty, express or implied, as to the information's accuracy or completeness, nor should the attached information serve as the basis of any investment decision. This document is intended exclusively for the use of the person to whom it has been delivered by Banyan Partners, and it is not to be reproduced or redistributed to any other person. The information set forth herein has been provided to you as secondary information and should not be the primary source for any investment or allocation decision. Past performance is not a guarantee of future performance.